Cargando…

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

The bioreductive drug tirapazamine (TPZ, SR 4233, WIN 59075) is a lead compound in a series of potent cytotoxins that selectively kill hypoxic rodent and human solid tumour cells in vitro and in vivo. Phases II and III trials have demonstrated its efficacy in combination with both fractionated radio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chinje, E C, Patterson, A V, Saunders, M P, Lockyer, S D, Harris, A L, Stratford, I J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374320/ https://www.ncbi.nlm.nih.gov/pubmed/10584872 http://dx.doi.org/10.1038/sj.bjc.6690819

Ejemplares similares

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
por: Saunders, M P, et al.
Publicado: (2000)

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995)

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
por: Patterson, A. V., et al.
Publicado: (1997)

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
por: Brown, J. M.
Publicado: (1993)

The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
por: Lartigau, E., et al.
Publicado: (1996)

Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.
por: Khan, S., et al.
Publicado: (1995)

The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
por: Keohane, A., et al.
Publicado: (1990)

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
por: Wang, J., et al.
Publicado: (1993)

Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
por: Minchinton, A. I., et al.
Publicado: (1992)

SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures.
por: Biedermann, K. A., et al.
Publicado: (1991)

The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.
por: Skarsgard, L. D., et al.
Publicado: (1993)

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
por: Friery, O P, et al.
Publicado: (2000)

Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions.
por: Silva, J. M., et al.
Publicado: (1993)

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity
por: Guise, Chris P., et al.
Publicado: (2020)

Tirapazamine-cisplatin: the synergy.
por: Gatzemeier, U., et al.
Publicado: (1998)

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
por: Kovacs, M S, et al.
Publicado: (1999)

Kinetics of Flavoenzyme-Catalyzed Reduction of Tirapazamine Derivatives: Implications for Their Prooxidant Cytotoxicity
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2019)

Changes in the Sensitivity of Intratumor Cells during Fractionated Tirapazamine Administration
por: Masunaga, Shin‐ichiro, et al.
Publicado: (2000)

Redox Proteomic Profile of Tirapazamine-Resistant Murine Hepatoma Cells
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2023)

Electronic structure and reactivity of tirapazamine as a radiosensitizer
por: Romero, José, et al.
Publicado: (2021)

Applicability of Combination with Tirapazamine in Boron Neutron Capture Therapy
por: Masunaga, Shin‐ichiro, et al.
Publicado: (1998)

Development and Validation of a Kilogram-Scale Synthesis of Tirapazamine
por: Lienard, Philippe, et al.
Publicado: (2020)

Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998)

Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells.
por: Barham, H. M., et al.
Publicado: (1996)

Ring-Selective Fragmentation in the Tirapazamine Molecule upon Low-Energy Electron Attachment
por: Arthur-Baidoo, Eugene, et al.
Publicado: (2021)

Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers
por: Ajnai, Giimel, et al.
Publicado: (2022)

Effects of Bioreductive Agents, Tirapazamine and Mitomycin C, on Quiescent Cell Populations in Solid Tumors, Evaluated by Micronucleus Assay
por: Masunaga, Shin‐ichiro, et al.
Publicado: (1997)

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
por: Moorsel, C J A van, et al.
Publicado: (1999)

Reactions in Tirapazamine Induced by the Attachment of Low‐Energy Electrons: Dissociation Versus Roaming of OH
por: Arthur‐Baidoo, Eugene, et al.
Publicado: (2020)

Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma
por: Abi-Jaoudeh, Nadine, et al.
Publicado: (2021)

The Development of Nonthermal Plasma and Tirapazamine as a Novel Combination Therapy to Treat Melanoma In Situ
por: Yehl, Matthew, et al.
Publicado: (2023)

Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth
por: Sommer, Paula, et al.
Publicado: (2010)

Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
por: Siim, B. G., et al.
Publicado: (1996)

Effect of Tirapazamine, Metformin or Mild Hyperthermia on Recovery From Radiation-Induced Damage in Pimonidazole-Unlabeled Quiescent Tumor Cells
por: Masunaga, Shin-ichiro, et al.
Publicado: (2017)

Comparison of in vivo Efficacy of Hypoxic Cytotoxin Tirapazamine and Hypoxic Cell Radiosensitizer KU‐2285 in Combination with Single and Fractionated Irradiation
por: Shibata, Toru, et al.
Publicado: (1996)

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
por: Kroep, J R, et al.
Publicado: (2000)

Tirapazamine-Doxorubicin Interaction Referring to Heart Oxidative Stress and Ca(2+) Balance Protein Levels
por: Sliwinska, Justyna, et al.
Publicado: (2012)

Tirapazamine-loaded CalliSpheres microspheres: Preparation and characterization as a chemoembolization agent for liver cancer
por: Zhang, Xin, et al.
Publicado: (2023)

Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
por: Olive, P. L.
Publicado: (1995)

Usefulness of Tirapazamine as a Combined Agent in Chemoradiation and Thermo‐chemoradiation Therapy at Mild Temperatures: Reference to the Effect on Intratumor Quiescent Cells
por: Masunaga, Shin‐ichiro, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_7mj17ok54c8q4n4di4s58d171g